Verve Therapeutics
ISIN US92539P1012
|WKN A3CSHT
Market cap (in EUR)
354.12 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 354.12 m |
| EPS, EUR | -2.17 |
| P/B ratio | 0.81 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 29.89 m |
| Net income, EUR | -183.70 m |
| Profit margin | -614.59% |
What ETF is Verve Therapeutics in?
There are 21 ETFs which contain Verve Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Verve Therapeutics is the Global X Genomics & Biotechnology UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
